Premium Nahrungsergänzungsmittel | artgerecht

Anti-CCP Antibodies – Diagnosis of Rheumatoid Arthritis

Anti-CCP antibodies are blood markers used for the early detection of rheumatoid arthritis. They are highly specific and help diagnose the condition at an early stage.

Regular tips about health Regular tips about health

Things worth knowing about "Anti-CCP antibodies"

Anti-CCP antibodies are blood markers used for the early detection of rheumatoid arthritis. They are highly specific and help diagnose the condition at an early stage.

What Are Anti-CCP Antibodies?

Anti-CCP antibodies (antibodies against cyclic citrullinated peptides, also known as ACPA – anti-citrullinated protein antibodies) are autoantibodies produced by the immune system against the body's own proteins. Specifically, they target citrullinated proteins – proteins in which the amino acid arginine has been converted into citrulline. They are among the most important laboratory markers for rheumatoid arthritis (RA).

Clinical Significance

Anti-CCP antibodies are a key diagnostic tool because they can be detected in the blood years before the clinical onset of rheumatoid arthritis. Compared to the rheumatoid factor, they offer significantly higher specificity for RA.

Sensitivity: approximately 60–75% for rheumatoid arthritis
Specificity: over 95% for rheumatoid arthritis
A positive result combined with a positive rheumatoid factor substantially increases diagnostic certainty
Positive anti-CCP antibodies may indicate a more aggressive disease course and an increased risk of joint destruction

Origin and Mechanism

In rheumatoid arthritis, the body's own proteins are citrullinated by the enzyme peptidylarginine deiminase (PAD). The immune system recognizes these altered structures as foreign and produces anti-CCP antibodies in response. These antibodies contribute to the inflammatory reaction in the joints and promote synovitis (inflammation of the joint lining), which is characteristic of RA.

Diagnosis: How Is the Test Performed?

Anti-CCP antibodies are detected from a simple blood sample. The serum is analyzed using an ELISA (enzyme-linked immunosorbent assay) or chemiluminescence-based immunoassays. Results are reported in units (U/ml), with reference values depending on the laboratory.

Reference Values (Guidance)

Negative: below 7 U/ml (laboratory-dependent)
Positive: above 10 U/ml (laboratory-dependent)
Borderline results should always be interpreted in the clinical context

When Is the Test Ordered?

Testing for anti-CCP antibodies is commonly ordered in the following situations:

Persistent joint pain or joint swelling, particularly in the small joints of the hands and feet
Suspected early rheumatoid arthritis
Evaluation in cases of family history of RA
Monitoring and risk assessment in patients already diagnosed with RA
Differential diagnosis against other joint diseases

Anti-CCP Antibodies and Disease Course

Patients with positive anti-CCP antibodies have a statistically higher risk of an erosive disease course, meaning permanent joint damage. Early diagnosis and timely initiation of disease-modifying therapy (DMARD therapy) can positively influence this progression. Anti-CCP-positive patients often respond well to biologics, particularly B-cell-depleting medications such as rituximab.

Distinction from Other Autoantibodies

In rheumatological diagnostics, anti-CCP antibodies are often measured alongside the rheumatoid factor (RF). While the rheumatoid factor can also be positive in other conditions (e.g., Sjogren syndrome, hepatitis), anti-CCP antibodies are considerably more specific for RA. In a seronegative course of RA, both markers may be negative, which does not exclude the diagnosis.

References

Nishimura K et al. - Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Annals of Internal Medicine, 2007.
Smolen JS et al. - EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Annals of the Rheumatic Diseases, 2020.
Aletaha D et al. - 2010 Rheumatoid Arthritis Classification Criteria: An American College of Rheumatology / European League Against Rheumatism Collaborative Initiative. Arthritis & Rheumatism, 2010.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.